A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

April 24, 2018

Study Completion Date

April 24, 2018

Conditions
Type 2 Diabetes
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (13)

33135

Suncoast Research Group, LLC, Miami

37909

New Phase Research & Development, Knoxville

43213

Aventiv Research, Columbus

63141

Clinical Research Professionals, St Louis

66606

Cotton O'Neil Diabetes and Endocrinology Center, Topeka

75230

Dallas Diabetes Endocrine Center, Dallas

78231

Consano Clinical Research, Shavano Park

83646

Solaris Clinical Research, Meridian

90057

National Research Institute, Los Angeles

91763

Catalina Research Institute, LLC, Montclair

92780

University Clinical Investigators, Inc., Tustin

93720

Valley Research, Fresno

06708

Chase Medical Research, LLC, Waterbury

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03311724 - A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter